DelveInsight said the global fusion biopsy market was about $798 million in 2025 and is projected to reach about $1.5 billion by 2034, implying growth of roughly 7% from 2026 to 2034. The report said demand is being driven by rising prostate cancer prevalence, broader use of mpMRI (multiparametric MRI)-targeted biopsy, and continued uptake of MRI-ultrasound fusion systems that aim to improve lesion targeting and reduce unnecessary biopsies. North America was the largest regional market in 2025 with a 42.67% share, while accessories were the largest product segment. The study also pointed to favorable reimbursement, expanding healthcare infrastructure, growing preference for minimally invasive diagnostics, and ongoing product innovation, including AI-enabled software and workflow tools, as factors supporting market expansion.